1
|
Toledano-Fonseca M, Gómez-España MA, Élez E, Grávalos C, García-Alfonso P, Rodríguez R, Losa F, Alés Díaz I, Graña B, Valladares-Ayerbes M, García-Ortiz MV, Polo E, Salgado M, Rivera F, Safont MJ, Salud A, Ruiz-Casado A, Tabernero JM, Riesco MC, Rodríguez-Ariza A, Aranda E. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients. Biomed Pharmacother 2023; 159:114272. [PMID: 36706629 DOI: 10.1016/j.biopha.2023.114272] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 01/10/2023] [Accepted: 01/17/2023] [Indexed: 01/27/2023] Open
Abstract
The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy has been previously demonstrated. However, the absence of validated biomarkers to predict greater outcomes is a major challenge encountered when using antiangiogenic therapies. In this study we investigated profiles of circulating microRNAs (miRNAs) to build predictive models of response to treatment and survival. Plasma was obtained from 98 metastatic CRC patients enrolled in a clinical phase II trial before receiving FOLFIRI plus aflibercept treatment, and the circulating levels of 754 individual miRNAs were quantified using real-time PCR. A distinct signature of circulating miRNAs differentiated responder from non-responder patients. Remarkably, most of these miRNAs were found to target genes that are involved in angiogenic processes. Accordingly, some of these miRNAs had predictive value and entered in predictive models of response to therapy, progression of disease, and survival of patients treated with FOLFIRI plus aflibercept. Among these miRNAs, circulating levels of hsa-miR-33b-5p efficiently discriminated between responder and non-responder patients and predicted the risk of disease progression. Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept.
Collapse
Affiliation(s)
- M Toledano-Fonseca
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain.
| | - M A Gómez-España
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain.
| | - E Élez
- Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
| | - C Grávalos
- Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i+12, Avenida de Córdoba, S/N, 28041 Madrid, Spain.
| | - P García-Alfonso
- Department of Medical Oncology, H. Gregorio Marañón, Calle del Doctor Esquerdo, 46, 28007 Madrid, Spain.
| | - R Rodríguez
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain.
| | - F Losa
- Department of Medical Oncology, ICO-CSI. H. Sant Joan Despí - Moisés Broggi, Carrer d'Oriol Martorell, 12, 08970 Sant Joan Despí, Barcelona, Spain.
| | - I Alés Díaz
- Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA, Campus de Teatinos, S/N, 29010 Málaga, Spain.
| | - B Graña
- Department of Medical Oncology, C. H. Universitario, Lugar, Xubias de Arriba, 84, 15006 A Coruña, Spain.
| | - M Valladares-Ayerbes
- Department of Medical Oncology, H. Virgen del Rocío, IBIS, Av. Manuel Siurot s/n, 41013 Sevilla, Spain.
| | - M V García-Ortiz
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain.
| | - E Polo
- Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain.
| | - M Salgado
- Department of Medical Oncology, C. H. Universitario de Ourense, Calle Ramón Puga Noguerol, 54, 32005 Orense, Spain.
| | - F Rivera
- Department of Medical Oncology, H. Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, 25, 39008 Santander, Spain.
| | - M J Safont
- Department of Medical Oncology, H. General Universitario, CIBERONC, Universidad de Valencia, Avenida de les Tres Creus, 2, 46014 Valencia, Spain.
| | - A Salud
- Department of Medical Oncology, H. Universitario Arnau de Vilanova, Avenida Alcalde Rovira Roure, 80, 25198 Lérida, Spain.
| | - A Ruiz-Casado
- Department of Medical Oncology, H. Puerta de Hierro Majadahonda, Calle Joaquín Rodrigo, 1, 28222 Majadahonda, Spain.
| | - J M Tabernero
- Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain.
| | - M C Riesco
- Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i+12, Avenida de Córdoba, S/N, 28041 Madrid, Spain.
| | - A Rodríguez-Ariza
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain.
| | - E Aranda
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain; Department of Medicine, Faculty of Medicine, University of Córdoba, E14004 Córdoba, Spain.
| | | |
Collapse
|
2
|
Jiménez-Fonseca P, Sastre J, García-Alfonso P, Gómez-España MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Díaz L, García-Paredes B, López López R, Guillot M, Gallego J, Alonso-Orduña V, Diaz-Rubio E, Aranda E. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials. Clin Colorectal Cancer 2023; 22:222-230. [PMID: 36944559 DOI: 10.1016/j.clcc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 01/30/2023] [Accepted: 02/10/2023] [Indexed: 02/25/2023]
Abstract
BACKGROUND The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs. <3) in previously untreated mCRC. PATIENTS AND METHODS The study involved 589 untreated mCRC patients included in the intention-to-treat population of 2 randomized clinical trials (phase III VISNU-1 [NCT01640405] and phase II VISNU-2 [NCT01640444] studies). RESULTS Of the 589 patients, 349 (59.2%) had bCTC≥3 and 240 (40.7%) had bCTC<3. Multivariate analysis showed that the bCTC count is an independent prognostic factor for overall survival (OS) (HR 0.59, 95% CI 0.48-0.72; P = 0.000) and potential for progression-free survival (PFS) (P = 0.0549). Median OS was 32.9 and 19.5 months in patients with bCTC<3 and bCTC≥3 (P <0.001), respectively. This effect was also observed comparing OS in RASwt patients from both studies. Other prognostic factors were: ECOG-PS, primary tumor site, number of metastatic sites and surgery of the primary tumor. Median OS was lower for patients treated with anti-VEGF versus anti-EGFR (22.3 vs. 33.3 months, P <0.0001) while there were no significant differences in PFS according to the targeted treatment received. CONCLUSION This post-hoc analysis of 2 randomized studies confirms the poor prognosis of patients with bCTC≥3 but this is not associated with other adverse independent prognostic factors such as RAS/BRAF mutations.
Collapse
Affiliation(s)
- P Jiménez-Fonseca
- Department of Medical Oncology. Hospital Universitario Central de Asturias, ISPA, Oviedo, 33011, Spain.
| | - J Sastre
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - P García-Alfonso
- Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain
| | - M A Gómez-España
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | - A Salud
- Department of Medical Oncology, Hospital Universitario Arnau de Vilanova, Lérida, 25198, Spain
| | - S Gil
- Department of Medical Oncology. Hospital Universitario Regional y Virgen de la Victoria, IBIMA, Málaga, 29010, Spain
| | - F Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, 39008, Spain
| | - J J Reina
- Department of Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Sevilla, 41009, Spain
| | - G Quintero
- Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, 27003, Spain
| | - M Valladares-Ayerbes
- Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain
| | - M J Safont
- Department of Medical Oncology, Hospital General Universitario de Valencia, CIBERONC, Universidad de Valencia, Valencia, 46014, Spain
| | - A La Casta
- Department of Medical Oncology, Hospital de Donostia, Guipúzcoa, 20014, Spain
| | - L Robles-Díaz
- Department of Medical Oncology. Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
| | - B García-Paredes
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - R López López
- Department of Medical Oncology and Translational Medical Oncology Group. Hospital Universitario Santiago de Compostela and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela, 15706, Spain
| | - M Guillot
- Department of Medical Oncology. Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain
| | - J Gallego
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, 03203, Spain
| | - V Alonso-Orduña
- Department of Medical Oncology, Hospital Universitario Miguel Servet. Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, 50009, Spain
| | - E Diaz-Rubio
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - E Aranda
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | | |
Collapse
|
3
|
Thompson CA, Mielicki MK, Rivera F, Fitzsimmons CJ, Scheibe DA, Sidney PG, Schiller LK, Taber JM, Waters EA. Leveraging Math Cognition to Combat Health Innumeracy. Perspect Psychol Sci 2023; 18:152-177. [PMID: 35943825 DOI: 10.1177/17456916221083277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Rational numbers (i.e., fractions, percentages, decimals, and whole-number frequencies) are notoriously difficult mathematical constructs. Yet correctly interpreting rational numbers is imperative for understanding health statistics, such as gauging the likelihood of side effects from a medication. Several pernicious biases affect health decision-making involving rational numbers. In our novel developmental framework, the natural-number bias-a tendency to misapply knowledge about natural numbers to all numbers-is the mechanism underlying other biases that shape health decision-making. Natural-number bias occurs when people automatically process natural-number magnitudes and disregard ratio magnitudes. Math-cognition researchers have identified individual differences and environmental factors underlying natural-number bias and devised ways to teach people how to avoid these biases. Although effective interventions from other areas of research can help adults evaluate numerical health information, they circumvent the core issue: people's penchant to automatically process natural-number magnitudes and disregard ratio magnitudes. We describe the origins of natural-number bias and how researchers may harness the bias to improve rational-number understanding and ameliorate innumeracy in real-world contexts, including health. We recommend modifications to formal math education to help children learn the connections among natural and rational numbers. We also call on researchers to consider individual differences people bring to health decision-making contexts and how measures from math cognition might identify those who would benefit most from support when interpreting health statistics. Investigating innumeracy with an interdisciplinary lens could advance understanding of innumeracy in theoretically meaningful and practical ways.
Collapse
Affiliation(s)
| | | | - Ferdinand Rivera
- Department of Mathematics and Statistics, San Jose State University
| | | | | | | | - Lauren K Schiller
- Department of Human Development, Teachers College, Columbia University
| | | | - Erika A Waters
- Department of Surgery, Washington University School of Medicine in St. Louis
| |
Collapse
|
4
|
Kasper S, Segal N, Rivera F, Tournigand C, Cheng Y, Deshpande P, Amirouchene Angelozzi N, Bento Pereira da Silva A, St-Pierre A, Kopetz S. 132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Segal N, Rivera F, Tournigand C, Kasper S, Chen Y, Deshpande P, Messmann R, Kopetz S. P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Moreno-Maldonado C, Ciria-Barreiro E, Rivera F, Luna S, Moreno C. Health assets in transgender adolescents: The role of socio-political engagement and competence. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab164.599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Research has shown lower mental health in transgender youth compared to cisgender peers. However, little is known about assets in their development. Self-determination theory posits that certain behaviours increase wellbeing, such as engaging in activities that meet the psychological need for competence and relatedness. This study analyses the mediator roles of political interest, sense of unity, and social self-efficacy in the association between gender identity and health.
Methods
Two samples of Spanish adolescents (15-18 years-old) were analysed. The first sample included 170 transgender and 575 cisgender (selected through a matching process) students who participated in the 2018 Health Behaviour in School-Aged Children study. The second sample included 67 transgender and 2,100 cisgender participants who collaborated in the UNICEF OPINA Barometer. Political interest, social self-efficacy, and sense of unity scales were used to measure community engagement and were considered as sources of resilience. Health-related quality of life (HRQL) was measured using the Kidscreen-10 scale. Data analysis was conducted using linear regressions and parallel mediation effects.
Results
Gender identity predicted well-being, showing lower HRQL in transgender adolescents than cisgender peers. Furthermore, sense of unity and social self-efficacy - but not political interest - significantly predicted wellbeing (higher levels have a positive impact on HRQL) in both groups, and indirectly mediated between gender identity and HRQL.
Conclusions
Sense of unity and social self-efficacy act as sources of resilience, increasing adolescent wellbeing. Thus, social inclusion and active citizenship can help adolescents to better cope with pressure and promote health. Moreover, the positive contributions of sense of unity and social self-efficacy was similar for cisgender and gender minority adolescents, suggesting similar underlying mechanisms.
Collapse
Affiliation(s)
- C Moreno-Maldonado
- Department of Evolutionary and Educational Psychology, University of Seville, Seville, Spain
| | - E Ciria-Barreiro
- Department of Evolutionary and Educational Psychology, University of Seville, Seville, Spain
| | - F Rivera
- Department of Evolutionary and Educational Psychology, University of Seville, Seville, Spain
| | - S Luna
- Department of Evolutionary and Educational Psychology, University of Seville, Seville, Spain
| | - C Moreno
- Department of Evolutionary and Educational Psychology, University of Seville, Seville, Spain
| |
Collapse
|
7
|
Ciria-Barreiro E, Moreno-Maldonado C, Rivera F, Moreno C. Effects of partner support on life satisfaction cisgender and transgender adolescents. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab164.880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Among gender minority youth the effect of family, school, peer, and community support are positively associated with emotional well-being, feelings of safety, or improved mental health. However, most research addressing the partner's role in gender minority adolescents have focused on risk behaviors (STI/HIV infection, unplanned pregnancy...) or intimate-partner violence. Because research has seldomly adopted a positive approach, little is known about the effect of partner support on transgender youth health?
Methods
The sample consisted of 170 transgender and 535 cisgender adolescents (selected through a matching process) 15 to 18 years-old who participated in the 2018 HBSC survey in Spain. Emotional Support was measured using the Network of Relationships Inventory (NRI) and Life-Satisfaction with Cantril Ladder. Means comparisons, hierarchical multiple linear regression and interaction tests were performed to contrast differences between the two groups, and to check the possible buffer effect of gender identity on the relationship between partner support and life satisfaction.
Results
Transgender adolescents scored lower in life satisfaction than cisgender peers. No differences were found between groups in the perception of emotional support, however emotional support was positively related to life satisfaction. Lastly, the relationship between partner support and life satisfaction was not moderated by gender identity.
Conclusions
This research showed that cisgender and transgender adolescents do not have differences in partner support, and highlights the overall positive benefit of partner support for health. Using a positive approach to better understand the impact of romantic relationships during adolescence will contribute to build strong network of assets for gender minority youths' positive development.
Key messages
Researching the development of trans adolescents requires the use of approaches that do not pathologize their realities. Individual and contextual assets should be considered to promote empowerment and well-being.
Collapse
Affiliation(s)
- E Ciria-Barreiro
- Department of Developmental and Educational Psychology, University of Seville, Seville, Spain
| | - C Moreno-Maldonado
- Department of Developmental and Educational Psychology, University of Seville, Seville, Spain
| | - F Rivera
- Department of Experimental Psychology, University of Seville, Seville, Spain
| | - C Moreno
- Department of Developmental and Educational Psychology, University of Seville, Seville, Spain
| |
Collapse
|
8
|
Benavides M, Gómez-España A, García-Alfonso P, García C, Vieitez J, Massuti Sureda B, Rivera F, Safont Aguilera M, Abad Esteve A, Granja Ortega M, Valladares-Ayerbes M, Carrato Mena A, González-Flores E, Robles L, Salud Salvia A, Alonso V, Montagut Viladot C, Asensio-Martinez E, Díaz-Rubio E, Aranda Aguilar E. 418P Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Moreno JA, Masoli P, Sferrazza C, Leiva H, Espinosa O, Hernande. . Rudnick P, Lizardo J, Rivera F, Plaz. d. lo. Reyes S, Cordova M, Sferrazza E, Chavez N, Sepulveda M, Jiliberto B. P–708 Comparison of reproductive outcomes after progestin-primed ovarian stimulation with dydrogesterone versus cetrorelix to inhibit spontaneous ovulation in oocyte donation. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Is dydrogesterone (DYG) equivalent compared to cetrorelix with respect to clinical pregnancy rate, ongoing pregnancy rate and live birth rate in oocyte donation (OD) cycles?
Summary answer
DYG is comparable to cetrorelix in terms of clinical pregnancy, but higher rates of ongoing pregnancy and live birth were observed in the DYG group
What is known already
Progestin-primed ovarian stimulation (PPOS) is an ovarian stimulation regimen based on a freeze-all strategy using progestin as an alternative to GnRH analog for suppressing a premature LH surge. DYG is an oral progestin that has been studied in PPOS protocols.
Published reports indicate that length of ovarian stimulation, dose of gonadotrophin needed and number of MII retrieved from PPOS cycles are comparable to short protocol of GnRH agonists during OD cycles. However, while some studies noted no differences in terms of live births, worse pregnancy rates have been reported in recipients of oocytes from PPOS cycles compared to GnRH antagonists.
Study design, size, duration
Prospective controlled study to assess the reproductive outcomes of OD recipients in which the donors were subjected to the DYG protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm. The OD cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter >18mm.
Participants/materials, setting, methods
202 oocyte donors were included, 92 under DYG and 110 under cetrorelix. The study was performed in a private infertility center between January 2017 and December 2020.
The main outcome included the rates of clinical pregnancy, ongoing pregnancy and live births. Secondary outcomes included the number of oocytes retrieved, number of MII, fertilization rate, length of stimulation and total gonadotropin dose. Differences were tested using a Student’s t-test or a Chi2 test, as appropriate.
Main results and the role of chance
Compared to antagonist cycles, cycles under DYG had fewer days of stimulation (9.9 ± 0.9 vs. 10.8 ± 1.1, p<.001) and a lower total gonadotropin dose (1654 ± 402.4 IU vs. 1844 ± 422 IU, p<.001). The number of MII retrieved was no different: 16.9 (SD 6.2) with DYG and 15.4 (SD 5.8) with cetrorelix (p = 0.072). Recipients and embryo transfer (ET) characteristics were also similar between groups. The mean number of MII assigned to each recipients was 6.7 (SD 1.8) in DYG and 6.6 (SD 1.7) in cetrorelix (P = 0.446). The fertilization rate was 66.2% in DYG versus 67.6% in cetrorelix (P = 0.68). Regarding the reproductive outcomes, the overall clinical pregnancy rate in DYG group (65/87: 74.7%) and cetrorelix group (66/104: 63.4%) (p = 0.118) was similar. Meanwhile, the DYG group compared to cetrorelix group had higher rates of ongoing pregnancy (63.2% vs 45.1%; p = 0.014) and live births (54,9% vs 37.8%; p = 0.040).
Limitations, reasons for caution
These results should be evaluated with caution. The limitations of this study include the limited number of participants enrolled and the limited data on pregnancy outcomes. A randomized controlled trial is necessary to provide more evidence on the efficacy of the DYG protocol.
Wider implications of the findings: The efficacy of PPOS protocol compared to GnRH-antagonist protocol in terms of reproductive outcomes has been little studied. PPOS using DYG yields comparable clinical pregnancy rates compared to cetrorelix in OD cycles. The differences found regarding the rates of ongoing pregnancy and live births should be further investigated.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- J A Moreno
- Universitat Autonoma de Barcelona, Gynecology and Obstetrics, Barcelona, Spain
| | - P Masoli
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - C Sferrazza
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - H Leiva
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - O Espinosa
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | | | - J Lizardo
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - F Rivera
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | | | - M Cordova
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - E Sferrazza
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - N Chavez
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - M Sepulveda
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| | - B Jiliberto
- Clinica de la Mujer, Medicina Reproductiva, Vina del Mar, Chile
| |
Collapse
|
10
|
Negro CL, Estrubia JF, Rivera F, Collins P. Effects of Chlorpyrifos Over Reproductive Traits of Three Sympatric Freshwater Crustaceans. Bull Environ Contam Toxicol 2021; 106:759-764. [PMID: 33754160 DOI: 10.1007/s00128-020-03091-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 12/20/2020] [Indexed: 06/12/2023]
Abstract
The exposure to environmentally relevant chlorpyrifos concentrations (0.03, 0.06 and 0.12 µg chlorpyrifos L-1) causes increases in precopulatory guardian behavior time, amplexus reformulation after exposure and in the number of ovigerous females in the amphipod Hyalella curvispina. Effects in incubation period, effective hatching and median lethal concentration on the decapods Macrobrachium borellii and Aegla uruguayana, both in adults and embryos, were achieved at higher concentrations than those found in the environment. Environmentally relevant chlorpyrifos concentrations appear not to affect decapods but several effects in reproductive traits of amphipods were observed.
Collapse
Affiliation(s)
- C L Negro
- Instituto Nacional de Limnología (CONICET-UNL), Paraje El Pozo s/n, 3000, Santa Fe, Argentina.
- Escuela Superior de Sanidad, Facultad de Bioquímica Y Ciencias Biológicas, UNL Paraje El Pozo s/n, 3000, Santa Fe, Argentina.
| | - J F Estrubia
- Instituto Nacional de Limnología (CONICET-UNL), Paraje El Pozo s/n, 3000, Santa Fe, Argentina
| | - F Rivera
- Instituto Nacional de Limnología (CONICET-UNL), Paraje El Pozo s/n, 3000, Santa Fe, Argentina
| | - P Collins
- Instituto Nacional de Limnología (CONICET-UNL), Paraje El Pozo s/n, 3000, Santa Fe, Argentina
- Escuela Superior de Sanidad, Facultad de Bioquímica Y Ciencias Biológicas, UNL Paraje El Pozo s/n, 3000, Santa Fe, Argentina
| |
Collapse
|
11
|
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO Open 2021; 6:100062. [PMID: 33711671 PMCID: PMC7970062 DOI: 10.1016/j.esmoop.2021.100062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/23/2020] [Accepted: 01/15/2021] [Indexed: 01/09/2023] Open
Abstract
Background We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). Patients and methods VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and <3 circulating tumour cells/7.5 ml blood were stratified by BRAF/PIK3CA status (wild-type versus mutated) and number of affected organs (1 versus >1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m2 then 250 mg/m2 weekly) plus FOLFIRI [irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory. Results Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups. Conclusions BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy. This study examined if BRAF/PIK3CA mutational status can guide therapy in RAS wild-type mCRC. BRAF mutations were associated with poorer survival outcomes, and were potentiated by PI3KCA mutations. Bevacizumab-FOLFIRI versus cetuximab-FOLFIRI had similar outcomes in BRAF /PIK3CA wild-type and BRAF /PIK3CA-mutated tumours. BRAF and PI3KCA mutations have a role as prognostic but not predictive factors.
Collapse
Affiliation(s)
- J Sastre
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
| | - P García-Alfonso
- Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - J M Viéitez
- Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M T Cano
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - F Rivera
- Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - J J Reina-Zoilo
- Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville, Spain
| | - A Salud-Salvia
- Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | - G Quintero
- Medical Oncology, Hospital Lucus Augusti, Lugo, Spain
| | - L Robles-Díaz
- Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
| | - M J Safont
- Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain
| | - A La Casta
- Medical Oncology, Hospital de Donostia, Guipúzcoa, Spain
| | - S Gil
- Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga, Spain
| | - E Polo
- Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain
| | - E Asensio-Martínez
- Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain
| | - B García-Paredes
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - R L López
- Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain
| | - M Guillot
- Medical Oncology, Hospital Son Espases, Palma de Mallorca, Spain
| | - M Valladares-Ayerbes
- Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain
| | - E Aranda
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - E Díaz-Rubio
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | | |
Collapse
|
12
|
Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol 2021; 31:79-87. [PMID: 31912800 DOI: 10.1016/j.annonc.2019.09.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 07/25/2019] [Accepted: 09/24/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Preclinical data suggest that dual blockade of the insulin-like growth factor-1 receptor (IGF-1R) and HER3 pathways has superior activity to IGF-1R blockade alone in pancreatic ductal adenocarcinoma (PDAC). We tested whether istiratumab, an IGF-1R- and ErbB3-bispecific antibody, can enhance the efficacy of standard of care (SOC) chemotherapy in patients with metastatic PDAC selected for high IGF-1 serum levels. PATIENTS AND METHODS CARRIE was an international, randomized, double-blind, placebo-controlled phase II study for patients with previously untreated metastatic PDAC. In part 1, 10 patients were evaluated for pharmacokinetics and safety. In part 2, patients with high free serum IGF-1 levels were randomized 1 : 1 to receive either istiratumab [2.8 g intravenously (i.v.) every 2 weeks] or placebo combined with gemcitabine/nab-paclitaxel at approved dose schedule. The co-primary endpoints were progression-free survival (PFS) in patients with high IGF-1 levels and PFS in patients with both high serum IGF-1 levels and heregulin (HRG)+ tumors. Key secondary endpoints were overall survival (OS), objective response rate (ORR) by RECIST v.1.1, and adverse events (AEs) rate. RESULTS A total of 317 patients were screened, with 88 patients randomized in part 2 (experimental arm n = 43; control n = 45). In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027]. In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42). Median OS and ORR for the overall population were similar between two arms. No significant difference in serious or grade ≥3 AEs was observed, although low-grade AEs leading to early discontinuation were higher in the experimental (39.5%) versus control arm (24.4%). CONCLUSIONS Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting. High serum IGF-1 levels did not appear to be an adverse prognostic factor when compared with non-biomarker-selected historic controls. CLINICAL TRIAL REGISTRATION NUMBERS ClinicalTrials.gov: NCT02399137; EUDRA CT: 2014-004572-34.
Collapse
Affiliation(s)
- M Kundranda
- Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA
| | - A C Gracian
- Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain
| | - S F Zafar
- Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA
| | - E Meiri
- Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA
| | - J Bendell
- GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA
| | - H Algül
- TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany
| | - F Rivera
- Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - E R Ahn
- Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA
| | - D Watkins
- Department of Medicine, Royal Marsden Hospital, Sutton, UK
| | - U Pelzer
- Charité - Universitätsmedizin Berlin, Germany
| | - V Charu
- Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA
| | - A Zalutskaya
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - G Kuesters
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - J M Pipas
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - S Santillana
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - V Askoxylakis
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - A H Ko
- Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA.
| |
Collapse
|
13
|
Yoshino T, Kim T, Yong W, Shiu KK, Jensen BV, Jensen LH, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere CDL, Rivera F, Elez E, Bendell J, Le D, Yang P, Farooqui M, Marinello P, Diaz L, Andre T. 112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
14
|
Zárraga M, Rivera F, Arroyo P, Miranda A, Baggio R, Alvares L, Moreno Y. SYNTHESIS AND CRYSTAL STRUCTURE ANALYSIS OF A NEW CHALCONE DERIVATIVE OF APOCYNIN. J Chil Chem Soc 2020. [DOI: 10.4067/s0717-97072020000204934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87. Ann Oncol 2020; 31:1094. [PMID: 32507672 DOI: 10.1016/j.annonc.2020.05.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- M Kundranda
- Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA
| | - A C Gracian
- Medical Oncology, Centro Integral Oncologico Clara Campal, Universidad CEU San Pablo, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain
| | - S F Zafar
- Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA
| | - E Meiri
- Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA
| | - J Bendell
- GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA
| | - H Algül
- TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany
| | - F Rivera
- Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - E R Ahn
- Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA
| | - D Watkins
- Department of Medicine, Royal Marsden Hospital, Sutton, UK
| | - U Pelzer
- Charité - Universitätsmedizin, Berlin, Germany
| | - V Charu
- Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA
| | - A Zalutskaya
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - G Kuesters
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - J M Pipas
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - S Santillana
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - V Askoxylakis
- Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA
| | - A H Ko
- Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA.
| |
Collapse
|
16
|
Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020; 22:236-244. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Accepted: 11/30/2019] [Indexed: 02/07/2023]
Abstract
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.
Collapse
Affiliation(s)
- M Martín-Richard
- Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.
| | - A Carmona-Bayonas
- Medical Oncology Department, Hospital J.M. Morales Meseguer, Murcia, Spain
| | - Ana B Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Centro de Investigación Biomédica en Red Cáncer, CB16/12/00398, Madrid, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche y Vega Baja, Alicante, Spain
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - J J Reina
- Medical Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - P Richart
- Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - M Alsina
- Medical Oncology Department, Hospital Universitario Vall D'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - J Sastre
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| |
Collapse
|
17
|
André T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Ravit G, Fountzilas G, Yong WP, Isaacs R, Österlund P, Liang JT, Creemers GJ, Rakez M, Van Cutsem E, Cunningham D, Tabernero J, de Gramont A. Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Ann Oncol 2019; 31:246-256. [PMID: 31959341 DOI: 10.1016/j.annonc.2019.12.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/03/2019] [Accepted: 12/15/2019] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT). PATIENTS AND METHODS Patients with curatively resected stage III CC were randomly assigned to FOLFOX4, FOLFOX4-bevacizumab, or XELOX-bevacizumab. RESULTS A total of 2867 patients were randomized: FOLFOX4: n = 955, FOLFOX4-bevacizumab: n = 960, XELOX-bevacizumab: n = 952. With a median of 6.73 years follow-up (interquartile range 5.51-10.54), 672 patients died, of whom 198 (20.7%), 250 (26.0%), and 224 (23.5%) were in the FOLFOX4, FOLFOX4-bevacizumab, and XELOX-bevacizumab arms, respectively. The 10-year overall survival (OS) rates were 74.6%, 67.2%, and 69.9%, (P = 0.003) and 5-year disease-free survival (DFS) rates were 73.2%, 68.5%, and 71.0% (P = 0.174), respectively. OS and DFS hazard ratios were 1.29 [95% confidence interval (CI) 1.07-1.55; P = 0.008] and 1.16 (95% CI 0.99-1.37; P = 0.063) for FOLFOX4-bevacizumab versus FOLFOX4 and 1.15 (95% CI 0.95-1.39; P = 0.147) and 1.1 (95% CI 0.93-1.29; P = 0.269) for XELOX-bevacizumab versus FOLFOX4, respectively. CC-related deaths (n = 542) occurred in 157 (79.3%) patients receiving FOLFOX4, 205 (82.0%) receiving FOLFOX4-bevacizumab, and 180 (80.4%) receiving XELOX-bevacizumab (P = 0.764), while non-CC-related deaths occurred in 41 (20.7%), 45 (18.0%), and 44 (19.6%) patients, respectively. Cardiovascular-related and sudden deaths during treatment or follow-up were reported in 13 (6.6%), 17 (6.8%), and 14 (6.3%) patients, in the FOLFOX4, FOLFOX4-bevacizuamb, and XELOX-bevacizumab arms, respectively (P = 0.789). Treatment arm, sex, age, histological differentiation, performance status, T/ N stages, and localization of primary tumor were independent prognostic factors of OS in stage III. CONCLUSIONS S-AVANT confirms the initial AVANT report. No benefit of the bevacizumab addition to FOLFOX4 adjuvant therapy in patients with stage III CC was observed in terms of DFS with a negative effect in OS, without increase in non-CC related deaths. CLINICAL TRIAL IDENTIFICATION NCT00112918.
Collapse
Affiliation(s)
- T André
- Sorbonne Université and, Department of Medical Oncology, Saint-Antoine Hospital, Paris, France.
| | - D Vernerey
- Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, INSERM UMR 1098, Besançon, France
| | - S A Im
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - G Bodoky
- Department of Medical Oncology, Combined Szent István and Szent László Hospitals, Budapest, Hungary
| | - R Buzzoni
- Department of Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy
| | - S Reingold
- Department of Medical Oncology, William Osler Health Centre Brampton Civic Hospital, Brampton, Canada
| | - F Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - J McKendrick
- Department of Medical Oncology, Eastern Health, Box Hill Hospital, Melbourne, Australia
| | - W Scheithauer
- Department of Medical Oncology, Vienna General Hospital (AKH), Medizinische Universität Wien, Vienna, Austria
| | - G Ravit
- Division of Oncology, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel
| | - G Fountzilas
- Department of Medical Oncology, Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - W P Yong
- Department of Hematology-Oncology, National University of Singapore, Singapore, Singapore
| | - R Isaacs
- Department of Medical Oncology, Palmerston North & Crest Hospitals, Palmerston North, New Zealand
| | - P Österlund
- Department of Oncology, Helsinki and Tampere University Hospitals, University of Helsinki, Helsinki/Tampere, Finland
| | - J T Liang
- Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
| | - G J Creemers
- Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands
| | - M Rakez
- Statistical Unit, ARCAD Foundation, Levallois-Perret, France
| | - E Van Cutsem
- Department of Internal Medicine, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium
| | - D Cunningham
- Department of Medicine, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, UK
| | - J Tabernero
- Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), UVic, IOB-Quiron, CIBERONC, TTD Group, Barcelona, Spain
| | - A de Gramont
- Statistical Unit, ARCAD Foundation, Levallois-Perret, France; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France
| |
Collapse
|
18
|
Segui MA, Cruz JJ, Alba E, Feliu J, Jara C, Rivera F, Rodriguez Lescure A, Lorenzo A, Martin M. Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. Clin Transl Oncol 2019; 22:1049-1058. [PMID: 31701365 PMCID: PMC7260140 DOI: 10.1007/s12094-019-02230-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 10/17/2019] [Indexed: 11/29/2022]
Abstract
PURPOSE The Spanish Society of Medical Oncology (SEOM, for its Spanish acronym) would like to attest to the relevance of training in Oncology as part of the undergraduate education in Medicine program and issue recommendations to improve said training, with the aim of responding better to the challenges that cancer poses to our society. MATERIALS AND METHODS The curricula of 42 schools of medicine were reviewed with interviews with at least one teaching medical oncologist from each faculty. The qualitative and opinion analysis was completed by means of an online questionnaire targeting lecturers, resident tutors, and residents in Medical Oncology (MO), enabling the detection of needs and areas for improvement at an organizational level and in terms of skill acquisition. RESULTS While the number of medical schools with a specific, mandatory program in MO has grown by up to 90%, it has not been accompanied by an increase in independent programs. Instead, they largely consist of programs shared with other specialties (61% of the medical faculties). In most of the undergraduate education programs, Oncology contents are fragmented and approached from the perspective of each organ system. CONCLUSIONS Despite the positive evolution in recent years, the heterogeneity in Oncology contents during undergraduate education training continues to be remarkable. Cross-sectional programs with an integral vision, taught in the final years of undergraduate medical education would be desirable. Among the recommendations for improvement of training in Medical Oncology, the SEOM proposes that updated, theoretical content be incorporated and clinical practice in Medical Oncology departments be promoted.
Collapse
Affiliation(s)
- M A Segui
- Medical Oncology Department, Parc Tauli Hospital Universitari, Universitat Autònoma de Barcelona, 08208, Sabadell, Spain.
| | - J J Cruz
- Medical Oncology Department, Hospital Clínico Universitario, Universidad de Salamanca, Salamanca, Spain
| | - E Alba
- Medical Oncology Department, Hospital Universitario Virgen de La Victoria, Málaga, Spain
| | - J Feliu
- Medical Oncology Department, Hospital Universitario la Paz, Universidad Autónoma de Madrid, CIBERONC, Madrid, Spain
| | - C Jara
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Madrid, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Rodriguez Lescure
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
| | - A Lorenzo
- Medical Oncology Department, Hospital Universitario de Puerto Real, Cádiz, Spain
| | - M Martin
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
19
|
André T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Geva R, Fountzilas G, Yong W, Isaacs R, Österlund P, Liang JT, Creemers GJ, Van Cutsem E, Cunningham D, Tabernero J, De Gramont A. Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Nonne D, Sanna F, Bardelli A, Milano P, Rivera F. Use of a Dual mobility cup to prevent hip early arthroplasty dislocation in patients at high falls risk. Injury 2019; 50 Suppl 4:S26-S29. [PMID: 30691923 DOI: 10.1016/j.injury.2019.01.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2018] [Revised: 12/07/2018] [Accepted: 01/12/2019] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Hip fracture is a common serious injury that occurs mainly in elderly. Dual-mobility hip arthroplasty or bipolar emiarthroplasty for its treatment remains a controversial decision. Co-morbidities and risk of fall represent additional aspects to be considered. The aim of our study was to determine the rate of mechanical complications for these two types of implants related to fall risk status of patients. PATIENTS AND METHODS Our study is a retrospective clinical trial of patients operated with a biarticular hemiarthroplasty or a dual-mobility total hip arthroplasty. Primary outcome was dislocation rate and need for any revision procedure. Patients were treated in a single center from January 2013 to March 2017. In all cases Morse Fall Scale (MSF) was calculated at patient admission to evaluate the risk of postoperative fall. Inclusion criteria to the study were: subcapital or femoral neck fracture of non-pathologic nature, patients with neuromuscular disorders or cognitive dysfunction, age > 75 years with MFS ≥ 45. The patients were reviewed postoperatively at 8 weeks, 6 months, 12 months, and then annually. Patients had clinical (Harris hip score) and radiological assessment. RESULTS The mean duration of the follow-up was 283 months. There were five dislocations in Group A (5,6%) and no dislocations in Group B (0%). All dislocations occurred within the first 6 months after surgery. The mean Harris Hip score was 81,7 in Group A patients and 79, 8 in Group B patients. DISCUSSION Treatment of hip fractures on non-cooperative patients still represents a dilemma. Falls and runaway motions represent high risk factors of dislocation. Use of dual-mobility cup has been found to be associated with a not statistically proved decrease of dislocation compared to traditional cups. CONCLUSION Dual-mobility cups might be considered a valuable option to prevent postoperative dislocation but further study is needed before extending the indications for dual-mobility following a fracture of the femoral neck, to assess the potential cost and complications of a longer procedure. So far, despite a lower dislocation risk, the authors actually cannot recommend widely use of a dual-motility cup instead of emiarthroplasty in high falls risk patients.
Collapse
Affiliation(s)
- D Nonne
- Orthopaedic Surgery Department, SS Annunziata Savigliano Hospital, Azienda Sanitaria Locale CN1, Via, Ospedali 14, Savigliano, Cuneo, Italy.
| | - F Sanna
- Orthopaedic Surgery Department, SS Annunziata Savigliano Hospital, Azienda Sanitaria Locale CN1, Via, Ospedali 14, Savigliano, Cuneo, Italy
| | - A Bardelli
- Orthopaedic Surgery Department, SS Annunziata Savigliano Hospital, Azienda Sanitaria Locale CN1, Via, Ospedali 14, Savigliano, Cuneo, Italy
| | - P Milano
- Orthopaedic Surgery Department, SS Annunziata Savigliano Hospital, Azienda Sanitaria Locale CN1, Via, Ospedali 14, Savigliano, Cuneo, Italy
| | - F Rivera
- Orthopaedic Surgery Department, SS Annunziata Savigliano Hospital, Azienda Sanitaria Locale CN1, Via, Ospedali 14, Savigliano, Cuneo, Italy
| |
Collapse
|
21
|
Argiles G, Margalef NM, Valladares-Ayerbes M, de Prado JV, Grávalos C, Alfonso PG, Santos C, Tobeña M, Sastre J, Benavides M, Cano T, Loupakis F, Garrote MR, Rivera F, Goldberg R, Falcone A, Bennouna J, Ciardiello F, Tabernero J, Aranda E. Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Moreno-Maldonado C, Moor I, Rivera F, Stevens GWJM, Morgan A, Braeckman L, De Clercq B. Systematic underestimation of social inequalities in adolescent health in 24 countries 2002-2014. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky212.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - I Moor
- Martin-Luther-University, Halle-Wittenberg, Germany
| | - F Rivera
- University of Huelva, Huelva, Spain
| | | | - A Morgan
- Glasgow Caledonian University, Glasgow, UK
| | | | | |
Collapse
|
23
|
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont M, Alcaide J, Gómez A, López R, Manzano J, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés J, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N, Díaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer 2018; 101:263-272. [DOI: 10.1016/j.ejca.2018.06.024] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 06/21/2018] [Accepted: 06/24/2018] [Indexed: 01/07/2023]
|
24
|
Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M. Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Chiritescu G, Dumon K, Mercadé TM, Lang I, Vivas CS, Papai Z, Janssens J, Hendrickx K, Pracht M, Van den Eynde M, Taïeb J, Moons V, Geboes K, Van Laethem J, Greil R, Cervantes A, Vergauwe P, Ferrante M, Vanderstraeten E, Fridrik M, Wöll E, Limón M, Rivera F, Sagaert X, Tejpar S, Van Cutsem E. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Garcia-Prats MD, Lopez-Carreira M, Mayordomo JI, Ballestin C, Rivera F, Diaz-Puente MT, Muñoz M, Cortes-Funes H, Martinez-Tello F. Leiomyosarcoma of the Soft Tissues in a Patient with Nevoid Basal-Cell Carcinoma Syndrome. Tumori 2018; 80:401-4. [PMID: 7839473 DOI: 10.1177/030089169408000516] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A 57-year-old man was admitted with complaints of progressive anorexia, weight loss and right flank pain. He had been treated for basal-cell carcinoma of the skin 19 years before. On physical examination, eight moles in the face, back and left thigh were found along with palmar pits. In addition, a painful induration in his right thigh was evident. Biopsy proved that six moles were basal-cell carcinomas and the thigh mass a high-grade leiomyosarcoma. Computed tomographs revealed multiple metastases in the lungs and the liver. The patient was treated with epirubicin, with partial response, and subsequently with ifosfamide. He died 17 months after diagnosis. Whereas the world literature records several cases of soft tissue tumors in patients with nevoid basal-cell carcinoma syndrome, this is the first report of a simultaneous occurrence of leiomyosarcoma and nevoid basal-cell carcinoma syndrome.
Collapse
Affiliation(s)
- M D Garcia-Prats
- Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Prat N, Paggi A, Ribera C, Acosta R, Ríos-Touma B, Villamarín C, Rivera F, Ossa P, Rieradevall M. The Cricotopus (Oliveiriella) (Diptera: Chironomidae) of the High Altitude Andean Streams, with Description of a New Species, C. (O.) rieradevallae. Neotrop Entomol 2018; 47:256-270. [PMID: 28905263 DOI: 10.1007/s13744-017-0548-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 07/18/2017] [Indexed: 06/07/2023]
Abstract
The genus Oliveiriella (Chironomidae, Orthocladiinae) was erected by Wiedenbrug & Fittkau (1997). The adults have characteristic black spots on their wings and other characteristics similar to the genus Cricotopus. Pupal skins are very characteristic with strong short spines in the anal lobe instead of setae, while larvae are distinguishable by the long anal papillae and the intense blue color of their body. However, Andersen et al (2013) consider Oliveiriella as a subgenera of Cricotopus. In this paper, using the sequences of the cox1 gene, we conclude that Oliveiriella should be considered a subgenus within Cricotopus, confirming its status in Andersen et al (2013). Furthermore, we describe Cricotopus (Oliveiriella) rieradevallae Prat & Paggi sp. n. from the Saltana river (Ecuador). The adult males, females, and preimaginal stages of the two species of subgenus Oliveiriella known from South America Cricotopus (O.) almeidai n. comb. from Peru, Brazil, and Argentina and Cricotopus (O.) sanjavieri n. comb. from Argentina are compared with those of Cricotopus (O.) rieradevallae sp. n. from Ecuador. The differences allow the distinction of the three species. The cox1 gene reveals that at least three different undescribed species of the same subgenus are present in the high-altitude tropical Andes. The morphology of the available pupae and pupal exuviae reveals the presence of several morphotypes that are candidates to be described as new species. A key used to distinguish these pupal morphotypes is provided, including the three described species. Additionally, the distribution of the subgenus is discussed.
Collapse
Affiliation(s)
- N Prat
- Freshwater Ecology and Management Research Group, Dept de Biologia Evolutiva, Ecologia i Ciències Ambientals, Univ de Barcelona, Barcelona, Spain.
| | - A Paggi
- Instituto de Limnología "Dr. R. A. Ringuelet" (ILPLA, CONICET, UNLP), La Plata, Argentina
| | - C Ribera
- Institut de Recerca de la Biodiversitat (IRbio), Dept de Biologia Evolutiva, Ecologia i Ciències Ambientals, Univ de Barcelona, Barcelona, Spain
| | - R Acosta
- Freshwater Ecology and Management Research Group, Dept de Biologia Evolutiva, Ecologia i Ciències Ambientals, Univ de Barcelona, Barcelona, Spain
| | - B Ríos-Touma
- Unidad de Biotecnología y Medio Ambiente (BIOMA), Facultad de Ingenierías y Ciencias Agropecuarias (FICA), Ingeniería Ambiental, Univ de las Américas, Quito, Ecuador
| | - C Villamarín
- Unidad de Biotecnología y Medio Ambiente (BIOMA), Facultad de Ingenierías y Ciencias Agropecuarias (FICA), Ingeniería Ambiental, Univ de las Américas, Quito, Ecuador
| | - F Rivera
- Research Group GEBIOME, Depto de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Univ de Caldas, Manizales, Colombia
| | - P Ossa
- Research Group GEBIOME, Depto de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Univ de Caldas, Manizales, Colombia
| | - M Rieradevall
- Freshwater Ecology and Management Research Group, Dept de Biologia Evolutiva, Ecologia i Ciències Ambientals, Univ de Barcelona, Barcelona, Spain
| |
Collapse
|
28
|
Medina JM, Gonzalez AB, Rivera F, Serrano R, Machado MM, García M. Abstract P6-11-15: Comparison of QoL according to treatment received. First cohort study in Mexico. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-11-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In México, there are more than 57 million women with breast cancer, and more than 7 million of these patients live in Mexico State; 12.4% of breast cancer diagnosis are being made in here. The diagnosis and treatment of patients with breast cancer changes their quality of life (QOL) on a physical, psychological, social and sexual basis.
Objectives: The main purpose of this study is to examine the changes in the QOL of breast cancer patients treated at the State of Mexico Cancer Center (ISSEMyM), applying the EORT QLQ-C30 and QLQ-BR23. The secondary aim of the study is to describe the Health-Related Quality of Life (HRQoL), including partner relationships, sexual function, and body image concerns of breast cancer survivors. (BCS).
Design: A longitudinal, prospective, descriptive and analytical cohort study was made; with bivariate analysis and correlations search. We used Kolmogorov-Smirnov test for normal continuous variables. To evaluate changes in follow-up we use ANOVA test of repeated measures and post-hoc analysis. Significance was set at p <0.05
Method: QOL questionnaires were applied every 4 months followed for a year, the first one being done before the patient was informed of confirmed breast cancer diagnosis. A sample of 112 women with primary breast cancer were enrolled. The sample type is probability, non-confessional, consecutive cases.
Results: Primary cancer treatment has a negative impact on QOL comparing to data collected at the basal assessment (before confirmatory diagnosis of cancer). Average age 54 years (25-85). FIGO stage in situ in 5%, Ia, IIa and IIb 18%, IIIa 8%, IIIb 6%, IIIc 12% and IV 15%. LuminalA 40%, LuminalB 24%, Her2 15%, Triple negative 21%. The mean overall health score was 64.7±26.7 at baseline and 65.8±19.3, 65.3±19.6, 72.1±15.1 at 4.8 and 12 months, respectively. Physical, emotional, cognitive, sexual and social functioning, as well as symptoms and sexual pleasure present statistical significance (p.0000) regardless of age, stage or treatment received.
Conclusions: This is the first longitudinal, prospective, descriptive and analytical cohort made in Mexico that assesses changes in QOL of breast cancer patients. There is a significant decrease in post-surgery physical function in our patients. However, there is no significant difference between the results observed in patients undergoing conservative surgery versus those who received radical surgery, nor for patients receiving surgery plus radiation therapy versus surgery plus systemic therapy. Also in the body image category component in our study, an important decrease in the QOL of the patients undergoing surgery is demonstrated, this is more evident in early stages of disease. In patients who recieved chemotherapy, symptoms were a negative influence in QOL and just near a half came to a basal status a year after treatment started. Finally, patients with surgery as first treatment have a faster return to their basal QOL.
This work opens an invaluable opportunity to improve our medical behavior towards breast cancer patients, treated at the ISSEMyM State of Mexico Cancer Center. It obliges us to create a multidisciplinary team that permanently assesses patients, identifying the aspects of their daily work, which alter their QOL.
Citation Format: Medina JM, Gonzalez AB, Rivera F, Serrano R, Machado MM, García M. Comparison of QoL according to treatment received. First cohort study in Mexico [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-15.
Collapse
Affiliation(s)
- JM Medina
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| | - AB Gonzalez
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| | - F Rivera
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| | - R Serrano
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| | - MM Machado
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| | - M García
- Centro Oncologico Estatal ISSEMyM, Toluca, Mexico; National Cancer Institute, Mexico, Mexico
| |
Collapse
|
29
|
Abad A, Martínez-Balibrea E, Viéitez J, Alonso-Orduña V, García Alfonso P, Manzano J, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol 2018; 29:439-444. [DOI: 10.1093/annonc/mdx737] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
30
|
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer 2018; 21:96-105. [PMID: 28393278 DOI: 10.1007/s10120-017-0718-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 04/03/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the efficacy and tolerance of triplets with epirubicin vs. doublets with platinum-fluoropyrimidine in a national AGC registry. METHODS Patients with AGC treated with polychemotherapy without trastuzumab at 28 hospitals in Spain between 2008 and 2016 were included. The effect of anthracycline-based triplets against doublets was evaluated by propensity score matching (PSM) and Cox proportional hazards (PH) regression. RESULT A total of 1002 patients were included (doublets, n = 653; anthracycline-based triplets, n = 349). The multivariable Cox PH regression failed to detect significantly increased OS in favor of triplets with anthracyclines: HR 0.90 (95% CI, 0.78-1.05), p = 0.20035. After PSM, the sample contained 325 pairs with similar baseline characteristics. This method was also unable to reveal an increase in OS: 10.5 (95% CI, 9.7-12.3) vs. 9.9 (95% CI, 9.2-11.4) months, HR 0.91 (CI 95%, 0.76-1.083), and (log-rank test, p = 0.226). Response rates (42.1 vs. 33.1%, p = 0.12) and PFS (HR 0.95, CI 95%, 0.80-1.13, log-rank test, p = 0.873) were not significantly higher with epirubicin-based regimens. The triplets were associated with greater grade 3-4 hematological toxicity, and increased hospitalization due to toxicity by 68%. The addition of epirubicin is viable, but 23.7% discontinued treatment because of adverse effects or patient decision. CONCLUSION Anthracyclines added to platinum-fluoropyrimidine doublets did not improve the response rate or survival outcomes in patients with AGC but entailed greater toxicity.
Collapse
Affiliation(s)
- A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain.
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - M Sánchez Cánovas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain
| | - R Hernández
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - C Pericay
- Medical Oncology Department, Corporació Sanitària Parc Taulí , Sabadell, Spain
| | - I Echavarria
- Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - A Lacalle
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - L Visa
- Medical Oncology Department, Hospital Universitario Del Mar, Barcelona, Spain
| | - A Rodríguez Palomo
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M Mangas
- Medical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain
| | - J M Cano
- Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain
| | - E Buxo
- Medical Oncology Department, Hospital Universitario Clinic, Barcelona, Spain
| | - F Álvarez-Manceñido
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - T García
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, IMIB, Avenida Marqués de los Vélez, 30008, Murcia, Spain
| | - J E Lorenzo
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - M Ferrer-Cardona
- Medical Oncology Department, Corporació Sanitària Parc Taulí , Sabadell, Spain
| | - A Viudez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - A Azkarate
- Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain
| | - A Ramchandani
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - D Arias
- Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
| | - F Longo
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - C López
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - R Sánchez Bayona
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - M L Limón
- Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - A Díaz-Serrano
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - A Fernández Montes
- Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain
| | - P Sala
- Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - P Cerdá
- Medical Oncology Department, Clínica Tecknon de Barcelona, Barcelona, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
| | | |
Collapse
|
31
|
Bayo J, Castaño MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol 2017; 20:467-475. [PMID: 28808872 DOI: 10.1007/s12094-017-1731-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 07/28/2017] [Indexed: 01/12/2023]
Abstract
PURPOSE Breast cancer is the most common neoplasm in women and has the highest associated mortality rate. Rapid detection programmes can provide early diagnosis and increase the chances of survival. There are no specific tumor biomarkers for the early phase of the disease. The primary aim of this study was to search a blood biomarker with levels that exceeded the normal range established in the general population that could be used to screen breast cancer. METHODS/PATIENTS Case-control study. Conventional as well as research (NGAL, EGFR and 8-OHdG) tumor biomarkers were analyzed. RESULTS A total of 126 women were enrolled (cases: 63 patients with local breast cancer; Controls: 63 healthy women). Significant differences were found in patients with higher levels of the conventional markers, Ca15.3, CEA, Cyfra 21.1 and NSE. However, when commercial cut-off values were used, only Ca 15.13 was significant. In the group of research biomarkers, significantly higher levels of EGFR were found in the control group, and of 8-OHdG in the case group. Using logistic regression analysis and a ROC curve, an equation composed of five markers, Ca 15.3, NSE, NGAL, EGFR and 8-OHdG, which yielded a correct diagnostic probability of breast cancer of 91.8% was obtained. CONCLUSIONS 8-OHdG has been identified as a new potential marker for screening early stage breast cancer. In addition, a model that combines five blood markers that can be used as a diagnostic test in certain groups of patients has been developed. New studies with a larger sample size are needed to verify the results obtained.
Collapse
Affiliation(s)
- J Bayo
- Oncology Service, Huelva Hospital Complex, Huelva, C/Ronda Norte, s/n, 21005, Huelva, Spain.
| | - M A Castaño
- Clinical Analysis Service, Huelva Hospital Complex, Huelva, Spain
| | - F Rivera
- Behavioural Science Methodology Area, University of Huelva, Huelva, Spain
| | - F Navarro
- Department of Integrated Sciences, Cell Biology, Faculty of Experimental Sciences, University of Huelva, Huelva, Spain
| |
Collapse
|
32
|
Calderon-Gonzalez R, Terán-Navarro H, García I, Marradi M, Salcines-Cuevas D, Yañez-Diaz S, Solis-Angulo A, Frande-Cabanes E, Fariñas MC, Garcia-Castaño A, Gomez-Roman J, Penades S, Rivera F, Freire J, Álvarez-Domínguez C. Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma. Nanoscale 2017; 9:10721-10732. [PMID: 28714508 DOI: 10.1039/c7nr02494k] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91-99 peptide (GNP-LLO91-99), which acts as a novel adjuvant for cancer therapy. GNP-LLO91-99, when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO91-99 nanoparticles caused tumour apoptosis and induced antigen- and melanoma-specific cytotoxic Th1 responses (P ≤ 0.5). We propose this adjuvant nanotherapy for preventing the progression of the first stages of melanoma.
Collapse
Affiliation(s)
- R Calderon-Gonzalez
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda. Cardenal Herrera Oria s/n, 39011 Santander, Cantabria, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Salvador J, Aparicio J, Baron FJ, García-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Muñoz M, Puente J, Rivera F, Rodríguez CA, Virizuela JA, Martín M, Garrido P. Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clin Transl Oncol 2017; 19:525. [DOI: 10.1007/s12094-017-1628-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Rivera F, Andres R, Felip E, Garcia-Campelo R, Lianes P, Llombart A, Piera JM, Puente J, Rodriguez CA, Vera R, Virizuela JA, Martin M, Garrido P. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. Clin Transl Oncol 2017; 19:508-518. [PMID: 28005259 PMCID: PMC5346109 DOI: 10.1007/s12094-016-1595-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 09/23/2016] [Indexed: 11/29/2022]
Abstract
PURPOSE The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them. METHODS The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board. RESULTS A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035. CONCLUSIONS Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologist's workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure.
Collapse
Affiliation(s)
- F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
- Sociedad Española de Oncología Médica (SEOM), C/ Velázquez, 7-3º planta, 28001, Madrid, Spain.
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain.
| | - R Andres
- Medical Oncology Department, Hospital Clínico Lozano Blesa, Zaragoza, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - E Felip
- Institut d'Oncologia, Vall d'Hebron University Hospital, Barcelona, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - R Garcia-Campelo
- Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Coruña, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - P Lianes
- Medical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - A Llombart
- Medical Oncology Department, Hospital Universitàri Arnau de Vilanova, Lleida, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J M Piera
- Medical Oncology Department, University Hospital Donostia, Donostia/San Sebastián, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J Puente
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - C A Rodriguez
- Medical Oncology Department, Hospital Clínico Universitario, Salamanca, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J A Virizuela
- Medical Oncology Department, Complejo Hospitalario Regional Virgen Macarena, Sevilla, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - M Martin
- Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - P Garrido
- Department of Medical Oncology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| |
Collapse
|
35
|
Rivera F, Peeters M, Douillard JY, Taieb J, Koukakis R, Demonty G, Siena S. Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Erratum to: SEOM guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2016; 18:426. [PMID: 26867938 PMCID: PMC4969810 DOI: 10.1007/s12094-016-1491-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- M Martin-Richard
- Medical Oncology Department, Hospital de la Santa Creu I, Sant Pau, 167, 08025, Barcelona, Spain.
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - C García-Girón
- Medical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain
| | - C Grávalos
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - C Gomez
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Jimenez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - J L Manzano
- Medical Oncology Department, Hospital Universitari Germans Trias I Pujol de Badalona, Barcelona, Spain
| | - C Pericay
- Medical Oncology Department, Hospital de Sabadell-Consorcio Sanitario Parc Taulì, Barcelona, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Carrato
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| |
Collapse
|
37
|
Ramal LM, López-Nevot MA, Sabio JM, Jáimez L, Paco L, Sánchez J, de Ramón E, Fernández-Nebro A, Ortego N, Ruiz-Cantero A, Rivera F, Martín J, Jiménez-Alonso J. Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. Lupus 2016; 13:934-40. [PMID: 15645749 DOI: 10.1191/0961203304lu2036oa] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We evaluated the influence of the hereditary make-up on the development of systemic lupus erythematosus (SLE) in two ethnic groups [Gypsy and white Caucasian Mediterranean (WCM) populations], living in the same geographic area. We compared 81 WCM and 25 Gypsy patients with SLE. The control group consisted of 185 healthy unrelated individuals, 105 WC and 80 Gypsies. In the Gypsy population, the onset of SLE occurred at earlier ages than in the other ethnic group (25.9 versus 32.0 years, P = 0.02), and showed lower SLEDAI peak values (4.9 versus 7.0, P = 0.016). The frequency of joint, kidney, gastrointestinal and eye involvement was significantly lower in Gypsy patients. In contrast, SLE-associated antiphospholipid syndrome, thrombosis and livedo reticularis were more frequent in Gypsies than in the majority ethnic group (WCM). In WCM patients, DRB1*1303- DQB1*0301 haplotype was associated with SLE ( P = 0.001, Pc = 0.038). We found SLE to be associated with DR5 ( P = 0.006, Pc = 0.05) in the Gypsy population as well as a protective effect of DPB1*0401 when DR5 was not present ( P = 0.008, Pc = 0.032). In conclusion, we found some clinical differences between WCM and Gypsy patients with SLE. Furthermore, HLA associations between HLA-DRB1-DQB1 and SLE were different for Gypsy people.
Collapse
Affiliation(s)
- L M Ramal
- Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Demonty G, Douillard JY. PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Sobrero A, Douillard JY, Rivera F, Forget F, Karthaus M, Valladares-Ayerbes M, Demonty G, Guan X, Peeters M. P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Rivera F, Karthaus M, Valladares-Ayerbes M, Gallego J, Koukakis R, Demonty G, Douillard JY. PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.31] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
41
|
Calera Urquizu L, Pajares I, Cebollero A, Vallejo C, Jaso R, Alvarez V, Trueba I, Alija V, Comin Ana M, Rivera F. P-155 Unresectable colorectal cancer liver metastases: retrospective review and survival analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Peeters M, Siena S, Douillard JY, Rivera F, Taieb J, Koukakis R, Demonty G, Köhne CH. PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Köhne CH, Rivera F, Taieb J, Siena S, Peeters M, Koukakis R, Demonty G, Douillard JY. PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Rivera F, Gallego J, Guillén-Ponce C, Benavides M, Lopez-Martin J, Kueng M. P-126 PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
García-Carbonero R, Vera R, Rivera F, Parlorio E, Pagés M, González-Flores E, Fernández-Martos C, Corral MÁ, Bouzas R, Matute F. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer. Clin Transl Oncol 2016; 19:135-148. [DOI: 10.1007/s12094-016-1518-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 04/30/2016] [Indexed: 12/31/2022]
|
46
|
Mirazón Lahr M, Rivera F, Power RK, Mounier A, Copsey B, Crivellaro F, Edung JE, Maillo Fernandez JM, Kiarie C, Lawrence J, Leakey A, Mbua E, Miller H, Muigai A, Mukhongo DM, Van Baelen A, Wood R, Schwenninger JL, Grün R, Achyuthan H, Wilshaw A, Foley RA. Inter-group violence among early Holocene hunter-gatherers of West Turkana, Kenya. Nature 2016; 529:394-8. [PMID: 26791728 DOI: 10.1038/nature16477] [Citation(s) in RCA: 139] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Accepted: 11/23/2015] [Indexed: 11/09/2022]
Abstract
The nature of inter-group relations among prehistoric hunter-gatherers remains disputed, with arguments in favour and against the existence of warfare before the development of sedentary societies. Here we report on a case of inter-group violence towards a group of hunter-gatherers from Nataruk, west of Lake Turkana, which during the late Pleistocene/early Holocene period extended about 30 km beyond its present-day shore. Ten of the twelve articulated skeletons found at Nataruk show evidence of having died violently at the edge of a lagoon, into which some of the bodies fell. The remains from Nataruk are unique, preserved by the particular conditions of the lagoon with no evidence of deliberate burial. They offer a rare glimpse into the life and death of past foraging people, and evidence that warfare was part of the repertoire of inter-group relations among prehistoric hunter-gatherers.
Collapse
Affiliation(s)
- M Mirazón Lahr
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK.,Turkana Basin Institute, Nairobi, Kenya
| | - F Rivera
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - R K Power
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - A Mounier
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - B Copsey
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - F Crivellaro
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - J E Edung
- National Museums of Kenya, Jomo Kenyatta House, PO Box 152-30500, Lodwar, Kenya
| | - J M Maillo Fernandez
- Departamento de Prehistoria y Arqueologia, UNED, c/ Paseo Senda del Rey, 7, 28040 Madrid, Spain
| | - C Kiarie
- Turkana Basin Institute, Nairobi, Kenya
| | - J Lawrence
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - A Leakey
- Turkana Basin Institute, Nairobi, Kenya
| | - E Mbua
- National Museums of Kenya, PO Box 40658-00100, Nairobi, Kenya
| | - H Miller
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - A Muigai
- Jomo Kenyatta University of Agriculture and Technology, PO Box 62000-00200, Nairobi, Kenya
| | - D M Mukhongo
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - A Van Baelen
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - R Wood
- Research School of Earth Sciences, The Australian National University, Building 142, Mills Road, Acton, Australian Capital Territory 2601, Australia
| | - J-L Schwenninger
- Research Laboratory for Archaeology and the History of Art, University of Oxford, Dyson Perrins Building, South Parks Road, Oxford OX1 3QY, UK
| | - R Grün
- Research School of Earth Sciences, The Australian National University, Building 142, Mills Road, Acton, Australian Capital Territory 2601, Australia.,Research Centre for Human Evolution, Environmental Futures Research Institute, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, Australia
| | - H Achyuthan
- Department of Geology, Anna University, Chennai, Tamil Nadu 600025, India
| | - A Wilshaw
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK
| | - R A Foley
- Leverhulme Centre for Human Evolutionary Studies, Department of Archaeology and Anthropology, University of Cambridge, Fitzwilliam Street, Cambridge CB2 1QH, UK.,Turkana Basin Institute, Nairobi, Kenya
| |
Collapse
|
47
|
Quiroga B, Vega A, Rivera F, López-Gómez JM. Crescentic glomerulonephritis: data from the Spanish Glomerulonephritis Registry. Intern Med J 2016; 45:557-62. [PMID: 25684569 DOI: 10.1111/imj.12725] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Accepted: 02/01/2015] [Indexed: 12/20/2022]
Abstract
BACKGROUND Crescentic glomerulonephritis (CGN) is a histological finding that implies rapid deterioration of renal function and can be related to different diseases, such as type 1 or anti-glomerular basement membrane antibody (Goodpasture) disease, type 2 or immune complex CGN and type 3 or pauci-immune disease. AIM The present study describes CGN and its characteristics based on the data from the Spanish Glomerulonephritis Registry. METHODS An analysis was made of all native renal biopsies obtained from patients during 1994-2013 and classified as CGN. A patient epidemiological and clinical data questionnaire was completed by the 120 centres involved. RESULTS A total of 21,774 biopsies was performed, of which 2089 (8.1%) corresponded to CGN (211 type 1, 177 type 2 and 1701 type 3). Renal function was poorer in type 1 compared with types 2 and 3, and proteinuria was higher in type 2 compared to types 1 and 3. Patients diagnosed with CGN type 3 were older than those with types 1 and 2, but less hypertensive than the type 2 patients. No differences in the urine test findings were found between types 1 and 2. Microhaematuria was the most frequent feature in general, as well as in type 3 compared with types 1 and 2. The main indication for biopsy was acute renal injury. Age was the only difference between type 1 patients with and without alveolar haemorrhage (53 [33-67] vs 64 [46-73], P = 0.008). CONCLUSION Although classified as the same entity, the different types of CGN have different features that must be taken into account.
Collapse
Affiliation(s)
- B Quiroga
- Hospital Gregorio Marañón, Madrid, Spain
| | - A Vega
- Hospital Gregorio Marañón, Madrid, Spain
| | - F Rivera
- Hospital General de Ciudad Real, Ciudad Real, Spain
| | | | | |
Collapse
|
48
|
Ramos P, Jiménez-Iglesias A, Rivera F, Moreno C. Evolución de la práctica de la actividad física en los adolescentes españoles / Physical Activity Trends in Spanish Adolescents. rimcafd 2016. [DOI: 10.15366/rimcafd2016.62.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
49
|
Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015; 17:996-1004. [PMID: 26691658 PMCID: PMC4689778 DOI: 10.1007/s12094-015-1456-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 11/13/2015] [Indexed: 02/06/2023]
Abstract
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum–fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the first-line treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement.
Collapse
Affiliation(s)
- M Martin-Richard
- Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, 167, 08025, Barcelona, Spain.
| | - A Custodio
- Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - C García-Girón
- Medical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain
| | - C Grávalos
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - C Gomez
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Jimenez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
| | - J L Manzano
- Medical Oncology Department, Hospital Universitari Germans Trias I Pujol de Badalona, Barcelona, Spain
| | - C Pericay
- Medical Oncology Department, Hospital de Sabadell-Consorcio Sanitario Parc Taulì, Barcelona, Spain
| | - F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Carrato
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| |
Collapse
|
50
|
Abad A, Massuti B, Gravalos C, Escudero P, Guillen-Ponce C, Manzano J, Ortiz M, Safont M, Gallego J, Sastre J, Pericay C, Duenas R, Rivera F, Losa F, Valladares-Ayerbes M, Gonzalez E, Robles L, Aranda E, Carrato A. 2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31050-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|